Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Agenus Inc (AGEN)

Agenus Inc (AGEN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Agenus Inc 3 FORBES ROAD LEXINGTON MA 02421 USA

www.agenusbio.com P: 781-674-4400 F: 781-674-4200

Description:

Agenus Inc., formerly known as Antigenics Inc., is engaged in the discovery, development and commercialization of immunotherapeutics for the treatment of life threatening and chronic medical conditions. Immunotherapeutics are drugs that work by modulating the immune system to fight diseases. The Company's product line includes Oncophage vaccine, a patient-specific therapeutic cancer vaccine. The Company is also developing Prophage, patient-specific therapeutic cancer vaccine; QS-21, vaccine adjuvant; and HerpV, a polyvalent off-the-shelf therapeutic heat shock protein-based vaccine for treatment of genital herpes which are all in the clinical testing stages. Agenus Inc. is headquartered in Lexington, Massachusetts.

Key Statistics

Overview:

Market Capitalization, $K 153,293
Enterprise Value, $K 90,103
Shares Outstanding, K 20,999
Annual Sales, $ 156,310 K
Annual Net Income, $ -245,760 K
Last Quarter Sales, $ 28,010 K
Last Quarter Net Income, $ -61,890 K
EBIT, $ -138,090 K
EBITDA, $ -124,500 K
60-Month Beta 1.32
% of Insider Shareholders 4.60%
% of Institutional Shareholders 61.46%
Float, K 20,033
% Float 95.40%
Short Volume Ratio 0.59

Growth:

1-Year Return -80.15%
3-Year Return -93.51%
5-Year Return -84.79%
5-Year Revenue Growth 324.99%
5-Year Earnings Growth 52.08%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -3.04 on 05/07/24
Next Earnings Date 08/13/24
Earnings Per Share ttm -12.84
EPS Growth vs. Prev Qtr -16.92%
EPS Growth vs. Prev Year 30.91%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-20 on 04/12/24

AGEN Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % 0.00%
Return-on-Assets % -77.55%
Profit Margin % -157.23%
Debt/Equity -0.07
Price/Sales 2.38
Price/Cash Flow N/A
Price/Book N/A
Book Value/Share -9.38
Interest Coverage -1.63
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar